A Randomised Double-blind (Sponsor Open), Placebo Controlled, Single Ascending Dose, First Time in Human Study in Participants With Mild to Moderate Asthma to Assess Safety, Tolerability, Immunogenicity, Pharmacokinetics and Pharmacodynamics of GSK3511294 Administered Subcutaneously

Trial Profile

A Randomised Double-blind (Sponsor Open), Placebo Controlled, Single Ascending Dose, First Time in Human Study in Participants With Mild to Moderate Asthma to Assess Safety, Tolerability, Immunogenicity, Pharmacokinetics and Pharmacodynamics of GSK3511294 Administered Subcutaneously

Recruiting
Phase of Trial: Phase I

Latest Information Update: 14 Jun 2018

At a glance

  • Drugs GSK-3511294 (Primary)
  • Indications Asthma
  • Focus Adverse reactions; First in man
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 15 Feb 2018 Planned primary completion date changed from 6 Dec 2018 to 24 Sep 2019.
    • 31 Jan 2018 Planned End Date changed from 24 Jul 2019 to 24 Sep 2019.
    • 25 Jan 2018 Planned End Date changed from 24 Jan 2019 to 24 Jul 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top